Clinical trial of ganglioside injection in the treatment of patients with severe craniocerebral injury
10.13699/j.cnki.1001-6821.2017.04.002
- VernacularTitle:神经节苷脂注射液治疗重症颅脑损伤患者的临床研究
- Author:
Yi FEI
1
;
Peng-Cheng WANG
;
Bao-Zhi CHEN
;
Jian-Nan CHEN
;
Qi-Bin PENG
;
Min ZENG
Author Information
1. 海南省人民医院神经科
- Keywords:
acute brain injury;
gangliosides injection;
neuron-specific enolase protein;
enzyme-linked immunosorbent assay
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(4):294-296
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the correlation between ganglioside (Gg) injection and serum neuron-specific enolase (NSE) and S100B protein concentration in patients with severe craniocerebral injury.Methods Sixty-eight patients with acute craniocerebral injury were randomly divided into control group (n =34) and treatment group (n =34).Patients in control group were intravenously infused mannitol injection 200 mL,twice a day and orally given norepinephrine 1.2 g,3 times a day.Patients in treatment group were given intravenous infusion of monosialoglycoside ganglion glucoside 100 mg,once a day.All patients were treated for 2 months.Serum NES and S100B protein levels were measured by enzyme-linked immunosorbent assay in two groups in 24,48,72,and 120 h after hospitalization.And the adverse drug reactions in two groups were observed.Results After 120 h treatment,the serum NSE levels in treatment group and control group were (13.21 ± 2.78),(18.52 ± 3.45) ng· mL-1.The S100 in treatment group and control group were (2.08 ±0.85),(3.76 ±2.14) ng · mL-1(P＜0.05).The effective rate was 82.35％ (28/34 cases) in treatment group,had significant difference with that in control group,which was 58.82％ (20/34 cases,P ＜ 0.05).The MMSE scores in treatment group after 2,4 weeks were 23.44 ± 3.15,27.41 ± 3.48,had significant difference with those in control group,which were 20.35 ± 2.35,22.24 ± 2.97 (P ＜ 0.01).There were no adverse drug reactions in two groups during the treatment.Conclusion Gg injection can effectively reduce the levels of serum NSE and S100B protein in patients with severe traumatic brain injury.
